MyBlueDotsMeiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy MyBlueDots7 months ago01 mins TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma invests in MPM BioImpact’s new technology and virology strategy to expand early-stage opportunities and enhance the global network. Go to Source Author: Post navigation Previous: Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNext: Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 2025
How noise, air pollution, heat and chemicals act together to damage the cardiovascular system MyBlueDots5 hours ago 0
Gene inhibitor found to boost immunotherapy for most aggressive form of lung cancer MyBlueDots5 hours ago 0
Children’s immune systems reveal new antibody targets for dengue vaccine development MyBlueDots5 hours ago 0